MedDataX Logo

Early Detection of Cognitive Dysfunction in Diabetes

NCT ID: NCT01830998

Last Updated: 2014-12-10

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

400 participants

Study Classification

OBSERVATIONAL

Study Start Date

2012-01-31

Study Completion Date

2014-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The rate of cognitive decline due to ageing is increased 1.5-fold to 2.0-fold in individuals with type 2 diabetes.There are no established specific treatment measures to prevent or ameliorate cognitive impairments in patients with diabetes. we want to detecte early clinical dementia in diabete.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Clinically relevant cognitive decrements in relation to diabetes mainly occur during two crucial periods in life: the period of brain development in childhood, and the period when the brain undergoes neurodegenerative changes associated with ageing.Potential leads for treatment are to optimise glycaemic control and avoid and treat vascular risk factors.we want to detecte early clinical dementia in diabete by MMSE and Olfactory function.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Dementia DM MCI

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Dementia Olfactory

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

control,MCI, Olfactory dsfunction

There are different groups:control,MCI, Olfactory dsfunction.

No interventions assigned to this group

control, MCI

control and MCI group.Glycaemic control

No interventions assigned to this group

control and MCI

treatment and without treatment

No interventions assigned to this group

MCI and Olfactory function

observation between MCI and Olfactory function groups.

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Patients with type 2 diabetes(Age\>50 years)

Exclusion Criteria

* with stroke or other complications.
Minimum Eligible Age

50 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Wuhan General Hospital of Guangzhou Military Command

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

zhipeng xu

doctor

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Wuhan general hospital of Guangzhou Command

Wuhan, Hubei, China

Site Status RECRUITING

tongji Medical University

Wuhan, Hubei, China

Site Status ENROLLING_BY_INVITATION

Wuhan general hospital of Guangzhou command

Wuhan,chongqing, Hubei, China

Site Status ACTIVE_NOT_RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

xuzhipeng Wuqiang lihonghua, doctor

Role: CONTACT

Phone: 13871168392

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

xu zhi peng, doctor

Role: primary

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

20130401

Identifier Type: -

Identifier Source: org_study_id